Essex Woodlands Management, Inc.
Long book
$250.5M
Q1 2026
Positions
5
Top-10 weight
100%
concentration
Last quarter
+7.8%
SPY +14.8%
Turnover
17%
of book per quarter
Strategy in plain words
auto-generated from filingsEssex Woodlands Management, Inc. is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $250.5M US long book across 5 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: BIOVENTUS INC - A, MIMEDX GROUP INC, EYEPOINT INC, TELA BIO INC, MEDICINOVA INC.
Over the last 9 quarters its long book ran on average 5.8pp per quarter behind the S&P 500, beating the index in 3 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-10.9%
Q2 2024
+14.0%
Q3 2024
+25.0%
Q4 2024
-19.7%
Q1 2025
-19.5%
Q2 2025
+10.5%
Q3 2025
+2.3%
Q4 2025
-21.2%
Q1 2026
+7.8%
Sector allocation
Healthcare 100%
Long book by quarter
What does Essex Woodlands own?
Q1 2026 13F13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 4, 2026 | 5 | $250.5M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 4, 2026 | 6 | $318.3M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 12, 2025 | 6 | $307.1M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 7, 2025 | 6 | $279.1M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 13, 2025 | 6 | $346.7M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 13, 2025 | 7 | $433.2M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 7 | $350.4M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 7 | $306.7M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 7 | $344.8M | canonical | SEC ↗ |